Keith Kaye, MD, MPH
Dr. Kaye is a Professor of Medicine in the Division of Infectious Diseases and Department of Medicine at University of Michigan Medical School. He is the Director of Research for the Division of Infectious Diseases. Dr. Kaye’s particular academic interests and skills include the prevention and management of healthcare-associated infections including those due to multi-drug resistant pathogens; antimicrobial stewardship; infections in the older adults; and surgical site infection.
Dr. Kaye received his medical degree from the University of Pennsylvania and completed his Internal Medicine residency and Infectious Diseases fellowship at Beth Israel Deaconess Medical Center in Boston, MA. During fellowship, Dr. Kaye earned a Masters in Public Health from the Harvard School of Public Health. Dr. Kaye has authored over 250 peer-reviewed articles and 18 book chapters and has presented original research at national and international conferences. Dr. Kaye has dedicated his entire career to infection prevention and antimicrobial stewardship and served as the Corporate Medical Director for Infection Prevention at Detroit Medical Center (DMC) from 2008-2016 and as Corporate VP of Quality and Patient Safety at DMC from 2012-2016. He is currently serving as President of the Society for Health Epidemiology of America (SHEA). He is recognized as an expert in healthcare epidemiology and antimicrobial resistance and has been invited to speak on these topics at venues throughout the world. Some of his most noteworthy work pertains to the polymyxin antimicrobials, nephrotoxic antibiotics discovered in the 1950s that have recently taken on growing recognition and importance due their high level of activity against practically untreatable multi-drug resistant (MDR) Gram-negative bacilli. He currently is the PI on 2 NIH-funded trials evaluating the treatment of infections due to extremely-drug resistant (XDR) Gram-negative bacteria with polymyxins. Dr. Kaye also conducts cutting edge research pertaining to infection prevention, and is currently the PI on an AHRQ-funded trial evaluating the impact UV disinfection of patient rooms on the acquisition of infection due to Clostridium difficile and MDR pathogens in hospitals.
No financial relationships have been disclosed.